Who are Placebo to Mirabegron's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Mirabegron tablet, nighttime dosing of mirabegron, daytime dosing of mirabegron, amibegron (SR58611A).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-to-mirabegron.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Placebo to Mirabegron — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo to Mirabegron (Placebo to Mirabegron) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-3 adrenergic receptor agonist. Area: Urology.

phase 3 Beta-3 adrenergic receptor agonist Beta-3 adrenergic receptor (ADRB3) Urology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo to Mirabegron (Placebo to Mirabegron) — Astellas Pharma Inc. Mirabegron is a beta-3 adrenergic receptor agonist that relaxes the detrusor muscle in the bladder to increase urine storage capacity.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo to Mirabegron TARGET	Placebo to Mirabegron	Astellas Pharma Inc	phase 3	Beta-3 adrenergic receptor agonist	Beta-3 adrenergic receptor (ADRB3)
Mirabegron tablet	Mirabegron tablet	Astellas Pharma Inc	marketed	Beta-3 adrenergic receptor agonist	Beta-3 adrenergic receptor (ADRB3)
nighttime dosing of mirabegron	nighttime dosing of mirabegron	Far Eastern Memorial Hospital	marketed	Beta-3 adrenergic receptor agonist	Beta-3 adrenergic receptor (ADRB3)
daytime dosing of mirabegron	daytime dosing of mirabegron	Far Eastern Memorial Hospital	marketed	Beta-3 adrenergic receptor agonist	Beta-3 adrenergic receptor (ADRB3)
amibegron (SR58611A)	amibegron (SR58611A)	Sanofi	phase 3	beta-3 adrenergic receptor agonist	beta-3 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-3 adrenergic receptor agonist class)

Astellas Pharma Inc · 2 drugs in this class
Far Eastern Memorial Hospital · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo to Mirabegron — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-mirabegron. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab